Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis

被引:0
|
作者
Zeydan, Burcu [1 ,2 ]
Azevedo, Christina J. [3 ]
Makhani, Naila [4 ,5 ]
Cohen, Mikael [6 ]
Tutuncu, Melih [7 ]
Thouvenot, Eric [8 ,9 ]
Siva, Aksel [7 ]
Okuda, Darin T. [10 ,11 ]
Kantarci, Orhun H. [2 ]
Lebrun-Frenay, Christine [6 ]
机构
[1] Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA
[3] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[4] Yale Sch Med, Dept Pediat, New Haven, CT USA
[5] Yale Sch Med, Dept Neurol, New Haven, CT USA
[6] Cote Azur Univ, Pasteur 2 Univ Hosp, Dept Neurol, MS Clin Nice,UR2CA URRIS, Nice, France
[7] Istanbul Univ, Cerrahpasa Sch Med, Dept Neurol, Istanbul, Turkiye
[8] Univ Montpellier, Nimes Univ Hosp Ctr, Dept Neurol, Nimes, France
[9] Montpellier Univ, IGF, CNRS, INSERM, Montpellier, France
[10] Univ Texas Southwestern Med Ctr, Neuroinnovat Program, Dallas, TX USA
[11] Univ Texas Southwestern Med Ctr, Multiple Sclerosis & Neuroimmunol Imaging Program, Dallas, TX USA
基金
美国国家卫生研究院;
关键词
RADIOLOGICALLY ISOLATED SYNDROME; INTRAMUSCULAR INTERFERON BETA-1A; 1ST DEMYELINATING EVENT; CLINICALLY DEFINITE; FOLLOW-UP; CONVERSION; ASSOCIATION; DIAGNOSIS; REVISIONS; PHASE;
D O I
10.1007/s40263-024-01117-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Radiologically isolated syndrome (RIS) is the earliest stage in the disease continuum of multiple sclerosis (MS). RIS is discovered incidentally in individuals who are asymptomatic but have typical lesions in the brain and/or spinal cord suggestive of demyelination. The 2009 and revised 2023 RIS criteria were developed for diagnosis. Presymptomatic individuals who fulfill the 2009 RIS criteria by having 3-4 of 4 dissemination in space McDonald 2005 MS criteria are still diagnosed with RIS using the revised 2023 RIS criteria. In presymptomatic individuals who do not fulfill the 2009 RIS criteria, the revised 2023 RIS criteria target to secure an accurate and timely diagnosis: In addition to (a) having one lesion in two of four locations (periventricular, juxtacortical/cortical, infratentorial, spinal cord), (b) two of three features (spinal cord lesion, cerebrospinal fluid (CSF)-restricted oligoclonal bands, and new T2 or gadolinium-enhancing lesion) should be fulfilled. Among laboratory biomarkers, CSF kappa-free light chain can also increase diagnostic accuracy. Once the diagnosis is confirmed, the established risk factors, including demographics, imaging, and laboratory biomarkers, should be evaluated for symptomatic MS transition and prognosis. Younger age, male sex, increased neurofilament-light chain, CSF abnormality, and the presence of infratentorial, spinal cord, or gadolinium-enhancing lesions on imaging are the main risk factors for transition to symptomatic MS. Two randomized clinical trials showed significant efficacy of disease-modifying treatments in delaying or preventing the development of the first clinical event in RIS. However, because some individuals remain as RIS, it is crucial to identify the individuals with a higher number of risk factors to optimize disease outcomes by early intervention while minimizing adverse events. Discussing each RIS case with an expert MS team is recommended because there is still a lack of clinical guidelines to improve care, counseling, and surveillance.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Update on Disease-Modifying Treatments for Multiple Sclerosis
    Carrithers, Michael D.
    [J]. CLINICAL THERAPEUTICS, 2014, 36 (12) : 1938 - 1945
  • [2] Disease-modifying treatments for progressive multiple sclerosis
    Comi, Giancarlo
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 1428 - 1436
  • [3] Cancer and multiple sclerosis in the era of disease-modifying treatments
    Lebrun, Christine
    Vermersch, Patrick
    Brassat, David
    Defer, Gilles
    Rumbach, Lucien
    Clavelou, Pierre
    Debouverie, Marc
    de Seze, Jerome
    Wiertlevsky, Sandrine
    Heinzlef, Olivier
    Tourbah, Ayman
    Fromont, Agnes
    Frenay, Marc
    [J]. JOURNAL OF NEUROLOGY, 2011, 258 (07) : 1304 - 1311
  • [4] Disease-modifying treatments for patients with multiple sclerosis in Spain
    Perez, Alejandro Santiago
    Casado, Santos Esteban
    Payero, Miriam Alvarez
    Pueyo, Angel Escolano Escolano
    Bernabe, Angel Guillermo Arevalo
    Zamora, Nuria Padulles
    Ruiz, Pilar Diaz
    Gonzalez, Ana Maria Lopez
    [J]. FARMACIA HOSPITALARIA, 2023, 47 (04) : 155 - 160
  • [5] Disease-modifying treatments in children and adolescents with multiple sclerosis
    Eraksoy, M
    Yapici, Z
    Ayta, S
    Akman-Demir, G
    Bilgili, E
    Topcular, B
    Ozcan, H
    [J]. JOURNAL OF NEUROLOGY, 2004, 251 : 62 - 63
  • [6] Established and novel disease-modifying treatments in multiple sclerosis
    Cross, A. H.
    Naismith, R. T.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2014, 275 (04) : 350 - 363
  • [7] Cancer and multiple sclerosis in the era of disease-modifying treatments
    Christine Lebrun
    Patrick Vermersch
    David Brassat
    Gilles Defer
    Lucien Rumbach
    Pierre Clavelou
    Marc Debouverie
    Jérôme de Seze
    Sandrine Wiertlevsky
    Olivier Heinzlef
    Ayman Tourbah
    Agnes Fromont
    Marc Frenay
    [J]. Journal of Neurology, 2011, 258 : 1304 - 1311
  • [8] Past and Present of Disease-Modifying Treatments in Multiple Sclerosis
    Eraksoy, Mefkure
    [J]. NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2011, 48 : 46 - 55
  • [10] Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
    Morillo Verdugo, Ramon
    Ramirez Herraiz, Esther
    Fernandez-Del Olmo, Raquel
    Roig Bonet, Montserrat
    Valdivia Garcia, Maria
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 261 - 272